Takayasu arteritis

Esatoğlu, Sinem Nihal; Hatemi, Gülen

doi:10.1097/bor.0000000000000852

Cited by 15 publications

(15 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinically, TA leads to stenosis, occlusion, or aneurysmal degeneration of large arteries, mainly the aorta and its major branches. 8,9 Coronary arteries are affected much more rarely, at a rate of 9% to 11%. 10 There are several clinical types of TA: stenosis or occlusion of proximal coronary segments involving the coronary ostia (type 1; most common), diffuse or focal coronary arteritis (type 2), and aneurysms of the coronary vessels (type 3; most rare).…”

Section: Discussionmentioning

confidence: 99%

Acute non-ST segment elevation myocardial infarction as the first manifestation of Takayasu arteritis in a 16-year-old female patient: a case report and literature review

Wang

Duan

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

Takayasu arteritis (TA) is now recognized worldwide and is a disease that mainly affects the aorta and its main branches. TA rarely involves the small or medium-sized vessels. Certain vascular lesions, such as arterial stenosis, occlusion, and aneurysm are common with TA. However, patients with new-onset TA who present with left main trunk acute non-ST segment elevation myocardial infarction are extremely rare. We report a 16-year-old female patient with non-ST segment elevation myocardial infarction due to severe stenosis of the left main coronary artery that was caused by TA. She was eventually diagnosed with TA and underwent successful coronary artery stenting combined with glucocorticoids and folate reductase inhibitor therapy. Over the 1-year follow-up, she experienced two episodes of chest pain and was admitted to the hospital. During the second hospitalization, coronary angiography (CAG) revealed 90% stenosis of the original left main trunk (LM) stent. Following percutaneous coronary angiography (PTCA), drug-coated balloon (DCB) angioplasty was performed. Fortunately, a clear diagnosis of TA was made, and treatment was initiated with an interleukin-6 (IL-6) receptor inhibitor. Early diagnosis and therapy for TA are emphasized.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute non-ST segment elevation myocardial infarction as the first manifestation of Takayasu arteritis in a 16-year-old female patient: a case report and literature review

Wang

Duan

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…Оптимальная продолжительность применения глюкокортикостероидов при АТ не установлена, однако нередко лечение приходится продолжать в течение длительного времени, если у пациента наблюдаются частые рецидивы заболевания [4,11]. У 60-80% пациентов, получающих монотерапию глюкокортикостероидами, развивается рецидив АТ [12], поэтому препараты этой группы уже в начале лечения обычно сочетают с иммуносупрессивными препаратами, прежде всего метотрексатом или азатиоприном. У молодых пациенток с АТ следует избегать назначения циклофосфамида, учитывая высокий риск развития бесплодия.…”

Section: аа-амилоидоз -редкая причина поражения почек у пациентки с а...unclassified

AA-amyloidosis as a rare cause of kidney disease in patient with Takayasu’s arteritis

Logina¹,

Bulanov²,

Kuznetsova³

et al. 2023

CPT

View full text Add to dashboard Cite

Takayasu’s arteritis (TAK) is a systemic large vessel vasculitis that usually develops at young age in females and affects aorta and its branches (pulseless disease). Patients with TAK frequently present with renal artery stenosis associated with renovascular hypertension and ischemic nephropathy, whereas glomerular and interstitial kidney disease is very rare. As any other chronic inflammatory diseases, TAK can be complicated with AA-amyloidosis manifesting by progressive proteinuria, nephrotic syndrome and chronic renal failure. AA-amyloidosis in patients with TAK and other immune-mediated inflammatory disease justifies intensification of immunosuppressive and antiinflammatory therapy (e.g. using interleukin-6 inhibitors) that is essential to prevent progression of kidney amiloidosis.

show abstract

“…Takayasu arteritis (TAK) is a large-vessel vasculitis, that affects mainly aorta and its proximal branches potentially resulting in severe complications such as aortic regurgitation ( 1 ). In addition to environmental factors, genetic variations, especially single nucleotide polymorphisms (SNPs), have a significant role in the disease pathophysiology ( 2 ). Among genetic components, HLA-B*52 is the most significantly associated and hence an established risk locus of TAK susceptibility among different populations ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Anti-integrin αvβ6 antibody in Takayasu arteritis patients with or without ulcerative colitis

Ishikawa,

Yoshida,

Yoshifuji

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundIt has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients. HLA-B*52 characterizes the co-occurrence, which is one of the common genetic features between these two diseases, indicating shared underlying pathologic mechanisms. Anti-integrin αvβ6 antibody (Ab) is present in sera of UC patients in a highly specific manner. We investigated if there were any associations between anti-integrin αvβ6 Ab and TAK, considering the risk HLA alleles.MethodsA total of 227 Japanese TAK patients were recruited in the current study and their serum samples were subjected to measurement of anti-integrin αvβ6 Ab by ELISA. The clinical information, including the co-occurrence of UC, was collected. The HLA allele carrier status was determined by Luminex or genotype imputation.ResultsThe information about the presence of UC was available for 165 patients, among which eight (4.84%) patients had UC. Anti-integrin αvβ6 antibody was identified in 7 out of 8 TAK subjects with UC (87.5%) while only 5 out of 157 (3.18%) TAK subjects without UC had the antibody (OR 121, p=7.46×10-8). A total of 99 out of 218 (45.4%) patients were HLA-B*52 carriers. There was no significant association between the presence of anti-integrin αvβ6 Ab and HLA-B*52 carrier status in those without UC (OR 2.01, 95% CI 0.33-12.4, p = 0.189).ConclusionsThe prevalence of anti-integrin αvβ6 Ab was high in TAK patients with UC, but not in the absence of concomitant UC. The effect of HLA-B*52 on anti-integrin αvβ6 Ab production would be minimal.

show abstract

Takayasu arteritis

Cited by 15 publications

References 49 publications

Acute non-ST segment elevation myocardial infarction as the first manifestation of Takayasu arteritis in a 16-year-old female patient: a case report and literature review

Acute non-ST segment elevation myocardial infarction as the first manifestation of Takayasu arteritis in a 16-year-old female patient: a case report and literature review

AA-amyloidosis as a rare cause of kidney disease in patient with Takayasu’s arteritis

Anti-integrin αvβ6 antibody in Takayasu arteritis patients with or without ulcerative colitis

Contact Info

Product

Resources

About